No Data
A steady and resilient U.S. Stocks market is providing support.
[Global Strategy for Emerging Markets] Today's emerging markets are expected to have a steady performance. Yesterday, on the 25th, the Dow Inc in the US stock market rose by 4.18 dollars (+0.01%) to 42,587.50 dollars, marking a slight increase for three consecutive days. The buying was supported by President Trump's suggestion of a flexible stance regarding 'reciprocal tariffs'. On the other hand, due to the deterioration in the consumer confidence Index ETF, concerns over economic slowdown caused the market to temporarily decline, but a drop in long-term interest rates supported the market, allowing it to recover into positive territory. Today's emerging markets are favored for buying.
D. Western Therapeutics Institute: Confirmation
D. Western Therapeutics Institute: Financial Report - 27th Term (2024/01/01 - 2024/12/31)
Individual stock information.
DWTI<4576.T> rebounded sharply. On the 18th, the company announced that it received notification from its licensing partner Kowa (Nagoya) that the administration to subjects in the Global Phase 3 clinical trial of the eye drop "K-321," which contains the active ingredient Rhok kinase inhibitor "Ripassizil hydrochloride hydrate," has been completed. Follow-up observations for the subjects are expected to be completed by the end of October. Trenders<6069.T> also rebounded. zenpl, a company engaged in planning, producing, and managing various events.
Earlier session / Active stocks and traded stocks [Active stocks and traded stocks]
*Daisue Construction <1814> 1962 +157 viewed as a Buy due to a significant Shareholding. *Tanseisha <9743> 1116 +66 continues to be positively received for its forecast of double-digit profit growth and planned dividend increase. *Yamashin Filter <6240> 631 +31 also has pointers such as the quarterly report. *Taiyo Yuden <6976> 2673 +131 is particularly lacking in materials, making short covering a dominant trend. *IHI <7013> 11790 +520 expansion in private aviation engine Components.
DWTI rebounds for the first time in five days around unchanged, with the Rhokinase inhibitor developed being administered to subjects at the licensing destination.
DWTI <4576.T> rebounded for the first time in five days, rising by 6 yen to reach 121 yen. After the close on the 18th, the company announced that it received notification from Kowa (Nagoya City, Aichi Prefecture), the licensing partner, that the administration to the subjects was completed in the Global Phase 3 clinical trial for the eye drop "K-321" containing the effective ingredient Rho kinase inhibitor "ripasudil hydrochloride hydrate," which was seen as significant news. This trial focuses on patients with Fuchs' endothelial corneal dystrophy.